THE TAKEAWAY
The promising data on leronlimab's ability to modulate the tumor immune microenvironment and potentially enhance immunotherapy responses in metastatic triple-negative breast cancer patients highlights the potential of this novel CCR5-targeting approach to address an unmet need in this aggressive form of the disease.
https://nationaltoday.com/us/ca/los-angeles/n...st-cancer/